SBT-272

Cardiolipin Binding and Cristae Stabilization#

SBT-272 is a small molecule engineered to partition preferentially into the inner mitochondrial membrane (IMM), where it binds cardiolipin — the signature phospholipid that organizes cristae folds and anchors the electron transport chain (ETC) supercomplexes. Under metabolic stress, cardiolipin gets peroxidized and displaced, cristae unfold, ETC supercomplexes disassemble, and ATP output collapses. SBT-272 occupies cardiolipin head-group sites and mechanically stabilizes that architecture, which is why downstream effects on respiration appear within hours of dosing rather than over weeks of transcriptional adaptation.

"SBT-272 preferentially partitions into mitochondria and stabilizes cristae structure by binding inner mitochondrial membrane cardiolipin, restoring mitochondrial respiratory control ratio after ischemic and oxidative insults in rodent CNS." — Zariwala H, Wakefield J, Redmon M, Abbruscato A., MDA Clinical & Scientific Conference, 2023

The practical reframe: this is not an antioxidant, not an ETC inhibitor, and not a biogenesis agent. It is a structural chaperone for the IMM — closer in spirit to a membrane stabilizer than to anything in the NAD+ or AMPK toolkit.

Restoration of Respiratory Control Ratio#

The functional readout for cardiolipin-targeted compounds is the respiratory control ratio (RCR) — the ratio of State 3 (ADP-driven) to State 4 (resting) oxygen consumption. A high RCR means tightly coupled mitochondria that make ATP efficiently; ischemia, oxidative stress, and aging all drive RCR down. In rodent CNS models, SBT-272 administration restores RCR after ischemia/reperfusion and after stereotactic endotoxin insult, indicating that the coupling between substrate oxidation and ATP synthesis is being functionally rescued, not just structurally propped up.

For users thinking in longevity-stack terms: this is the same mechanistic endpoint that elamipretide / SS-31 hits in cardiac and renal tissue. SBT-272 extends that endpoint into the brain compartment.

Brain Penetrance — The Differentiator from SS-31#

The SS-peptide family (elamipretide / SS-31 and analogs) has a well-known limitation: poor CNS exposure. The aromatic-cationic tetrapeptide scaffold concentrates beautifully in cardiac and renal mitochondria but barely crosses the blood-brain barrier. SBT-272 was designed around that constraint.

"The Szeto-Schiller (SS) peptide family, including elamipretide and its analogs, targets mitochondrial cardiolipin to stabilize cristae architecture; new derivatives are being developed with enhanced brain penetrance." — Mitchell W, Tamucci JD, Ng EL, Liu S, Birk AV, Szeto HH, May ER, Alexandrescu AT, Alder NN., eLife, 2022

The PK signature reflects this. Plasma half-life is short (≤3 h in rat), but brain tissue acts as a deep compartment: brain C24h sits around 136 ng/g after a 10 mg/kg dose, versus ~11 ng/mL in plasma at the same timepoint. CSF:plasma ratio climbs ~100-fold over 24 hours. The functional consequence is that once-daily dosing maintains 10–100 nM trough exposure in brain tissue — the same window that delivers efficacy in disease models — despite plasma clearance suggesting a much shorter dosing interval would be needed.

This is the mechanistic argument for slotting SBT-272 into a longevity stack alongside (not replacing) SS-31: cardiolipin stabilization in cardiac/renal tissue from elamipretide, cardiolipin stabilization in CNS from SBT-272.

TDP-43, Motor Neuron Mitochondria, and Neuroinflammation#

The headline preclinical data are in the hTDP-43 mouse model of ALS, where 60 days of chronic dosing produced measurable structural and inflammatory rescue in motor cortex.

"Chronic SBT-272 treatment in hTDP-43 mice improved mitochondrial structure and motility in diseased upper motor neurons, reduced both astrogliosis and microgliosis, and markedly decreased TDP-43 pathology in the motor cortex." — Genç B, Jara JH, Sanchez SS, Lagrimas AKB, Gözütok Ö, Koçak N, Zhu Y, Özdinler PH., Neurobiology of Disease, 2023

Three things matter in that result. First, mitochondrial motility improved — diseased motor neurons typically have stalled, fragmented mitochondria that can't reach distal axonal compartments, and that trafficking defect was partially reversed. Second, glial inflammation markers (GFAP, Iba1) dropped, suggesting cardiolipin stabilization upstream is sufficient to quiet the downstream neuroinflammatory cascade. Third, in head-to-head in vitro work, SBT-272 outperformed both edaravone and AMX0035 (Relyvrio) at restoring diseased upper motor neuron health — an important benchmark because those are the two compounds with actual ALS approvals.

For the longevity-focused reader, the readout is that cardiolipin-targeted intervention can shift not just bioenergetic markers but also neuroinflammatory ones — relevant to anyone thinking about mitochondrial dysfunction as an upstream driver of glial activation in aging brain.

What the Mechanism Does Not Do#

Worth being explicit, because the mitochondrial-longevity space is full of compounds with overlapping marketing claims:

• No direct antioxidant activity. SBT-272 does not scavenge ROS the way MitoQ or SkQ1 does. The reduction in oxidative damage is downstream of structural stabilization, not free-radical quenching.
• No mitochondrial biogenesis signal. Unlike PQQ, urolithin A, or AMPK activators, there is no published evidence that SBT-272 upregulates PGC-1α or mitochondrial mass.
• No mitophagy induction. Unlike urolithin A, the mechanism is preservation of existing mitochondria, not clearance of damaged ones.
• No hormonal activity. Cardiolipin binding does not engage steroid receptors, GPCRs, or HPTA signaling — which is why the compound is mechanistically sex-neutral and carries no PCT or ancillary requirement.

The cleanest mental model: SBT-272 is what you reach for when the goal is keeping existing mitochondria functional under stress, not building more of them, not clearing damaged ones, and not quenching radicals after the fact.

Common (most users)#

Phase 1 healthy-volunteer dosing was described by the sponsor as "generally safe and well tolerated" across single- and multiple-ascending doses, with no specific AE table published in peer-reviewed form (Stealth, 2022). Preclinical work in rat, mouse, and non-human primate at therapeutic exposures has not surfaced notable adverse findings (MDA abstract, Zariwala et al.).

By analogy to the SS-peptide family (SS-31 / elamipretide), the following are the realistic low-grade signals to anticipate in any subcutaneous protocol:

• Injection-site irritation — minor erythema or transient soreness at the SC site. Rotate sites; small-gauge insulin syringe; warm the solution to room temperature before injection.
• Mild headache — reported with related cardiolipin-targeted peptides; usually resolves within the first week of dosing. Hydration and a lower starting dose mitigate.
• Transient fatigue or "off" feeling — early in a protocol as mitochondrial bioenergetics shift. Front-loading the dose in the morning is preferred over evening administration.
• GI flutter (nausea, loose stool) — uncommon at SC doses; more likely if oral formulations are used.

Uncommon (dose-dependent or individual)#

Because no published human dose-response curve exists outside Phase 1, the items below are extrapolated from SS-peptide-class behavior and should be treated as theoretical risks worth monitoring:

• Elevated CK or transient transaminase bump — not characteristic of cardiolipin stabilizers, but worth a baseline + quarterly CMP and CK panel given the absence of long-term human data.
• Sleep disruption — if dosed in the evening; shift to AM administration.
• Blood pressure drift — neither hypertensive nor hypotensive effects are documented mechanistically, but anyone stacking on top of AAS or other compounds with cardiovascular load should monitor.
• Subjective neurological "noise" — brain-penetrant mitochondrial modulators occasionally produce mild cognitive or mood shifts in the first 1–2 weeks. Persistent symptoms warrant pausing the protocol.

Bloodwork cadence: baseline CMP, CBC, lipid panel, CK before initiation, repeated at 4–6 weeks and at cycle end.

Rare but serious#

No serious adverse events have been published in the SBT-272 literature. The items below are flagged as unknown territory given the early-stage clinical status:

• Anaphylaxis / hypersensitivity to vehicle or impurity — particularly relevant given sourcing risk (see contraindications). Warning signs: rash, swelling, dyspnea within minutes of injection. Stop immediately.
• Unexplained CNS symptoms — persistent headache, vision changes, or focal neurological signs. Discontinue and investigate.
• Cardiac arrhythmia signal — not reported, but the SS-peptide family has been developed extensively in cardiac indications, so any new palpitations or syncope warrant pausing and ECG.

Hard contraindications#

• Pregnancy and lactation. No reproductive toxicology has been disclosed publicly. Treat as fully unstudied — do not run in any subject with conception potential.
• Unverified sourcing. This is the dominant real-world risk. There is no legitimate research-chemical supply chain for SBT-272. Any vial labeled "SBT-272" without third-party mass-spec and HPLC identity confirmation must be assumed to be mislabeled SS-31, a generic SS-peptide analog, or an unknown compound. Confirm identity before any laboratory work; do not extrapolate from elamipretide-class community reports.
• No long-term human safety data. Phase 1 covers short-duration healthy-volunteer dosing only. Chronic exposures beyond 60 days have only been characterized in rodents. Cycle length should not exceed the 4–8 week window the preclinical data supports.
• Stacking with other investigational mitochondrial modulators without cause. Layering SBT-272 on top of SS-31, MOTS-c, urolithin A, and NAD+ precursors simultaneously produces an uninterpretable signal — if something goes wrong, the offending agent cannot be identified. Introduce one variable at a time.

Gender, HPTA, and PCT considerations#

The cardiolipin-binding mechanism does not engage androgen, estrogen, or progesterone receptors and does not interact with the HPTA. No PCT is required and no sex-specific dosing signals exist in the preclinical record. The compound is mechanistically appropriate for both male and female subjects at the same mg/kg exposures used in the ALS mouse work. The pregnancy/lactation exclusion above is the only sex-specific hard line, and it exists because of absence of reproductive toxicology data, not because of a known teratogenic signal.